Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
出版年份 2018 全文链接
标题
Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
作者
关键词
-
出版物
MODERN PATHOLOGY
Volume 31, Issue 6, Pages 965-973
出版商
Springer Nature
发表日期
2018-02-06
DOI
10.1038/s41379-018-0013-y
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
- (2017) Hisato Kawakami et al. INVESTIGATIONAL NEW DRUGS
- A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event
- (2017) Francesco Gelsomino et al. INVESTIGATIONAL NEW DRUGS
- Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma
- (2017) Brandon M. Huffman et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma
- (2016) Matteo Simonelli et al. Immunotherapy
- Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition
- (2016) Barbara Melosky et al. JOURNAL OF CLINICAL ONCOLOGY
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Ipilimumab-associated Hepatitis
- (2015) Melanie Johncilla et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab associated hepatitis: imaging and clinicopathologic findings
- (2013) Kyung Won Kim et al. INVESTIGATIONAL NEW DRUGS
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
- (2012) David E. Kleiner et al. DIGESTIVE DISEASES AND SCIENCES
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
- (2010) Sergio A. Quezada et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Simplified criteria for the diagnosis of autoimmune hepatitis
- (2008) Elke M. Hennes et al. HEPATOLOGY
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
- (2008) Lawrence Fong et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started